Body composition and functional capacity in patients with Crohn's disease using Infliximab

Cruz, Melissa Mercadante Santana; Slob, Gabriela Lazzaron; Santos, Cristiane Teixeira dos; Fontana, Pâmela Dias; Ramos Junior, Odery; Rabito, Estela Iraci.
Rev. Ciênc. Méd. Biol. (Impr.) ; 22(1): 52-57, jun 22, 2023.
Artigo em Inglês | LILACS | ID: biblio-1442845

Similares

  1. Como está a qualidade da dieta de pacientes com doença de Crohn em remissão clínica e em uso de infliximabe?
  2. The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn's disease.
  3. Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics
.
  4. Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
  5. Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease.
  6. Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative.
  7. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
  8. CT enterography-based radiomics combined with body composition to predict infliximab treatment failure in Crohn's disease.
  9. Trough Concentration Response in Infliximab and Adalimumab Treated Children With Inflammatory Bowel Disease Following Treatment Adjustment: A Pharmacokinetic Model.
  10. Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.